The Daily Docket: KV Pharmaceutical Unveils Bankruptcy Plan
News | 09 January 2013
K-V Pharmaceutical Co. Monday unveiled a bankruptcy-exit plan that hinges on a $20 million rights offering and has already earned the support of a group of senior noteholders. Read the Daily Bankruptcy Review article here. (Daily Bankruptcy Review and ...
Click on the link to read the full article at Wall Street Journal (blog)
(This link will open in a new window)
- US Supreme Court says patent settlement can "sometimes" be illegal
- InSite Vision joins Merck & Co and Pfizer in patent infringement law suit against
- Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
- Additional indications in Japan for Roche's Avastin and Astellas' Prograf
- Highlights of EHA meeting: Novartis' Jakavi; Bristol-Myers and AbbVie's elotuzumab; Janssen's ibrutinib
